Saturday, September 08, 2012

AMD Update 21: Good News for Patients With Stargardt’s Disease

Stargardt’s disease (also known as Stargardt macular dystrophy) is the most common form of inherited juvenile macular degeneration. Inherited as an autosomal recessive trait, it is a severe form of macular degeneration that begins in late childhood, leading to legal blindness. Stargardt’s disease is symptomatically similar to age-related macular degeneration, and it affects approximately one in 10,000 children.

There are currently two approaches underway to treat Stargardt’s, the use of embryonic stem cells to produce retinal pigmented epithelial (RPE) cells, which are injected subretinally, to replace damaged RPE cells (which take care of the photoreceptor cells) (sponsored by Advanced Cell Technology), and the use of gene therapy, to replace mutations in the ABCA4 gene, which cause Stargardt’s disease, and produces a dysfunctional protein (RPE) that cannot perform its transport function. As a result, photoreceptor cells degenerate, and vision loss occurs (sponsored by Oxford BioMedica).

A few days ago, the Foundation Fighting Blindness announced a new program to 1) study people with Stargardt’s to gain information about how best to treat it, 2) to better understand the disease’s progression, and 3) to identify potential patients for future clinical trials.

Here is how FFB described their ProgStar program, an important step in understanding and treating Stargardt’s disease.

Sept. 4, 2012 - The Foundation Fighting Blindness Clinical Research Institute is launching a natural history study of people affected by Stargardt disease. Known as ProgStar, the study has three primary goals: 1) determine the best outcome measures to accelerate evaluation of emerging treatments; 2) better understand disease progression for selecting future clinical trial participants; and 3) identify potential participants for forthcoming clinical trials.

The study, taking place in multiple locations worldwide, will combine both prospective and retrospective analyses. The prospective portion, for which physicians will track the progression of disease in participants, will last at least a year, with a possible one-year extension. Physicians will also retrospectively analyze disease progression by reviewing participants' past medical records. 

"Stargardt disease has a complex effect on the retina," says Dr. Hendrik Scholl, of the Wilmer Eye Institute, Johns Hopkins Hospital, ProgStar's protocol principal investigator and study director. "Also the rate of disease progression can vary between people and is difficult to measure. These issues can make selection of clinical trial outcome measures and participants challenging. But ProgStar will help us design better human studies of potential treatments and increase our chances of success."

During ProgStar, researchers will evaluate a number of outcome measures, including retinal images, visual fields and visual acuity.

ProgStar is preparing to enroll its first participants in early 2013. The study's clinician-scientists, listed below, will recruit as many as 300 patients from their practices. No additional recruitment will be conducted, and ProgStar will not involve administration of potential therapies.

Principal investigators for the study are:

    Dr. Paul Bernstein, University of Utah (Salt Lake City)
    Dr. David Birch, Retina Foundation of the Southwest (Dallas)
    Dr. Gerald Fishman, The Chicago Lighthouse (Chicago)
    Dr. Samuel Jacobson, University of Pennsylvania (Philadelphia)
   Dr. Michel Michaelides, Moorfields Eye Hospital (London, United Kingdom)
    Dr. José Sahel, Institut de la Vision (Paris, France)
    Dr. Hendrik Scholl, Johns Hopkins Hospital (Baltimore)
    Dr. Janet Sunness, Greater Baltimore Medical Center (Baltimore)
    Dr. Eberhart Zrenner, University of Tübingen (Tübingen, Germany)

Participants for the study are being recruited only from the existing patient populations of the nine principal investigators listed above. People who are not existing patients of one of these physicians are not eligible for the study.

Participating in study design are Drs. Frederick Ferris and Brian Brooks, of the National Eye Institute, Dr. Johanna Seddon, of Tufts Medical Center, and Dr. Richard Weleber, of Oregon Health & Science University.

Dr. Srinivas Sadda, of the Doheny Eye Institute, University of Southern California, will be analyzing imaging and visual field data collected from the study centers.


At 1:45 PM, Anonymous Anonymous said...

I've read some good stuff here. Definitely worth bookmarking for revisiting.

At 11:57 PM, Anonymous Anonymous said...

This is *not* just a juvenile onset disease, unless you consider 40s "late childhood." I noticed my first blind spot around age 41 and was diagnosed with Stargardt's in a test ordered by Dr. Jampol of Northwestern University Hospital four years later. So I'm pretty sure that's what I have, and even Wikipedia says onset is sometimes delayed until around age 40. It would be nice if you corrected your article.

At 10:43 PM, Anonymous Anonymous said...

I couldn't have asked for a better blog. You happen to be always at hand to offer excellent guidance, going straight away to the point for easy understanding of your site visitors. You're really a terrific pro in this subject matter. Many thanks for being there visitors like me.

At 3:46 PM, Anonymous Anonymous said...

March 18, 2013
I am so grateful to have discovered this blog and other information regarding 'Stargardt' disease. My family has never heard of this disease ..until the past few days,.. through our own research determination.

My 46yr old daughter has been progressively losing her vision for the past 5yrs. UCLA, USC, ...& others, have been 'perplexed' from the beginning of this sad and frustrating saga. All the pics and tests seemed to yield nothing that any of the doctors could identify. One Dr. at UCLA said he saw that 'something' didn't look right, that 'something' was sorta showing up,...but ?? So began our frantic search for help. Thru these years, re-testing has continued to frustrate and present nothing conclusive. Appx 2-yrs ago, someone said,..hmmmm...your autoimmune system is attacking your eyes. That led to the drug 'prednisone' to suppress the villainous immune attack, if not to 'stop' whatever was at least 'slow' its progression. Also, 'infusion' was recommended and done. Now, with all the 'immune-suppressant' treatment,.. my daughter is vulnerable to 'everything'.. now she is chronically fighting off some illness or another,...which then sends her back to Drs. for more drugs to counter this and that.
It is demoralizing after each series of pictures etc,. to hear, 'your retina is clear', we just have to wait & 'SEE'? !... 'For my daughter, 'SEE' being the operative word. A week ago at last,.. revealed...'spots'. Still, mention of a 'diagnosis', mention of 'Stargardt disease'. We are heading back to another appt soon but now have a medical term to offer.....'Stargardt disease'. This new knowledge causes us to feel more 'empowered' and 'hopeful'.

Please, continue posting anything and everything in the way of updates and new research. Thank you.

At 3:56 PM, Blogger Irv Arons said...

I recommend that all visitors also take a look at the website for The Foundation Fighting Blindness for additional information about Stargardt's disease. The url is

Irv Arons


Post a Comment

<< Home